Arch Therapeutics withdraws 510(k) with plans to resubmit after further discussions with FDA. Arch Therapeutics, Inc., developer of novel liquid, gel, and solid hemostatic and wound care devices, has withdrawn its 510(k) notification for its medical device AC5 Topical Gel, from the Food and Drug Administration (FDA) with plans to submit a new 510(k) as soon…